Pricing Log in Create free account

AC Immune (ACIU) vs Lineage Cell Therapeutics, Inc. (LCTX)

AC Immune and Lineage Cell Therapeutics, Inc. are both Biotechnology companies. AC Immune and Lineage Cell Therapeutics, Inc. are of similar size ($250.5M and $249.4M). Lineage Cell Therapeutics, Inc. grew revenue faster over the last twelve months: 19.9% against −85.6%. Lineage Cell Therapeutics, Inc. has the higher net margin (−246.6% vs −1,783.7%) and the lower return on invested capital (−186.8% vs 0.00%). Across the 18 metrics below, Lineage Cell Therapeutics, Inc. leads on 10 and AC Immune on 8.

Valuation

Metric ACIU LCTX Biotechnology median
P/E n/m n/m 8.50
P/S 50.83 18.69 9.71
P/B 5.30 4.09 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 31.31 14.81 9.21
Earnings yield (34.31%) (14.67%) (33.15%)
Free cash flow yield (35.48%) (9.98%) (25.50%)

Profitability

Metric ACIU LCTX Biotechnology median
Gross margin 100.00% 99.46% 65.16%
Operating margin (1,745.75%) (205.23%) 0.00%
Net margin (1,783.66%) (246.58%) 0.00%
Free cash flow margin 0.00% (186.43%) 0.00%
Return on equity 0.00% (60.35%) (56.36%)
Return on assets 0.00% (32.75%) (48.04%)
Return on invested capital 0.00% (186.79%) 0.00%

Growth

Metric ACIU LCTX Biotechnology median
Revenue growth (TTM) (85.56%) 19.87% 6.02%
EPS growth (last fiscal year) (44.83%) (211.11%) 30.26%
Revenue growth, 5-year CAGR (47.84%) 51.46% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACIU LCTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.93 6.61 4.72
Net debt to EBITDA 1.37 2.64 0.96

Dividend

Metric ACIU LCTX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ACIU LCTX Biotechnology median
Market cap 249.35m 250.45m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack